We don't have biomarkers to guide us. We really have a lot of options ... comparing alternative post-CDK4/6 progression treatment strategies versus standard-of-care, single-agent endocrine therapy.

Targeting the estrogen receptor and HER2 pathways improved progression-free survival in patients with HR-positive, ...

New DESTINY-Breast06 analysis showed trastuzumab deruxtecan doubled PFS versus chemotherapy in patients with rapid ...

The model uses clinical and genomic features to predict whether patients will respond to first-line CDK4/6 and endocrine therapy.

Seven in vitro studies evaluate the “effects of pesticides on the anatomy and physiology of hepatocytes and adipocytes” and ...

A phase 2 trial showed ctDNA detection in HR-positive early breast cancer was linked to larger tumors, higher residual cancer ...

The CDK4/6 inhibitor palbociclib (Ibrance; Pfizer) led to a significant improvement in progression-free survival (PFS) in patients with HR-positive, HER2-positive metastatic breast cancer when added ...

The addition of palbociclib (Ibrance) to current standard-of-care therapy following induction chemotherapy resulted in a ...

Results of the a phase III clinical trial called EMBER-3 indicate the promise and efficacy of a drug called imlunestrant. This is a new kind of oral selective estrogen receptor degrader (SERD), used ...

Various biomarkers, including T-cell inflamed 18-gene expression profile, were positively prognostic for improved pathologic complete response (pCR) and event-free survival (EFS), with or without the ...

The aim of this Research Topic was to accelerate pioneering research and deepen our understanding of endocrine-related cancers. By spotlighting groundbreaking studies on targeted therapies, biomarker ...